pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer

Bakry Ibrahim, Omar Y Mady, Murtaza M Tambuwala, Yusuf A Haggag

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
40 Downloads (Pure)


Background: Parenteral administration of chemotherapeutic drugs, 5-fluorouracil (5-FU) and leucovorin (LV), is commonly used to treat large bowel carcinomas such as colon cancer (CC) and colorectal carcinoma (CRC).
Aim: Our study aims to design a novel nanoparticulate drug-delivery vehicle for oral use capable of colon-specific release.
Methods: A modified double-emulsion solvent evaporation method was used in the preparation of pH-responsive Eudargit® S100 polymeric nanoparticles, loaded with 5-FU/LV combination (5-FU/LV-loaded Eudargit S100 NPs).
Results: Our optimized drug-loaded NP showed a pH-responsive drug release and exhibited significantly more cytotoxic actions in cancer-cell lines than free drugs.
Conclusion: These findings open the way for conducting clinical trials for colon malignancies treated with nanoparticles.
Original languageEnglish
Pages (from-to)367-381
Number of pages15
Issue number6
Early online date3 Feb 2022
Publication statusPublished (in print/issue) - 31 Mar 2022

Bibliographical note

Funding Information:
Financial support for research work was provided by Tanta University, Egypt. Open Access was funded by Ulster University under their Read and Publish agreement with the publisher. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Publisher Copyright:
© 2022 The Authors.


  • 5-fluorouracil
  • Research Article
  • colon targeting
  • eudragit S100
  • large bowel carcinoma
  • leucovorin
  • nanoparticles
  • oral delivery


Dive into the research topics of 'pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer'. Together they form a unique fingerprint.

Cite this